Globus Medical, Inc. (GMED) Stock Score, Valuation & Financial Research
Globus Medical, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 63/100.
Quick answer for GMED
Globus Medical, Inc. currently has a Wall Street Score of 63/100. The stored market price is $74.19. Its financial score is 36/100. Its valuation score is 87/100. The latest WSS change is -1.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Globus Medical, Inc. does
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic al
GMED financial snapshot
- Wall Street Score:
- 63/100
- Current price:
- $74.19
- Market capitalization:
- $10.01B
- Revenue:
- $3.14B
- Net income:
- $535.5M
- Free cash flow:
- $588.8M
- Cash:
- $507.7M
- Total debt:
- $111.2M
- EPS:
- 3.98
- P/E ratio:
- 18.6x
- Financial score:
- 36/100
- Valuation score:
- 87/100
- Revenue score:
- 41/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $588.8M, showing positive cash generation.
- The balance sheet shows $507.7M of cash versus $111.2M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -1.2 points: GMED decreased 1.2 points because Capital declined by 6 points, Valuation declined by 5 points.
What the numbers mean
Its current valuation score is 87/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GMED
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.